Discrimination of Normal, Benign, and Malignant Breast Tissues by Raman Spectroscopy

M. V.P. Chowdary, K. Kalyan Kumar, Jacob Kurien, Stanley Mathew, C. Murali Krishna

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Breast cancers are the leading cancers among females. Diagnosis by fine needle aspiration cytology (FNAC) is the gold standard. The widely practiced screening method, mammography, suffers from high false positive results and repeated exposure to harmful ionizing radiation. As with all other cancers survival rates are shown to heavily depend on stage of the cancers (Stage 0, 95%; Stage IV, 75%). Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management. Raman spectra of normal, benign, and malignant breast tissue show significant differences. Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues. Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm-1) is indicated in normal tissue and proteins (stronger amide I, red shifted ΔCH2, broad and strong amide III, 1002, 1033, 1530, 1556 cm-1) are found in benign and malignant tissues. The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm-1) and presence of excess proteins (amide I, amide III, red shifted ΔCH2, 1033, 1002 cm-1) is indicated in benign spectra. The multivariate statistical tool, principal components analysis (PCA) is employed for developing discrimination methods. A score of factor 1 provided a reasonable classification of all three tissue types. The analysis is further fine-tuned by employing Mahalanobis distance and spectral residuals as discriminating parameters. This approach is tested both retrospectively and prospectively. The limit test, which provides the most unambiguous discrimination, is also considered and this approach clearly discriminated all three tissue types. These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues.

Original languageEnglish
Pages (from-to)556-569
Number of pages14
JournalBiopolymers
Volume83
Issue number5
DOIs
Publication statusPublished - 05-12-2006

Fingerprint

Raman Spectrum Analysis
Raman spectroscopy
Breast
Tissue
Amides
Breast Diseases
Lipids
Screening
Cytology
Breast Neoplasms
Proteins
Neoplasms
Mammography
Ionizing radiation
Fine Needle Biopsy
Ionizing Radiation
Principal Component Analysis
Needles
Principal component analysis
Cell Biology

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Biomaterials
  • Organic Chemistry

Cite this

Chowdary, M. V.P. ; Kumar, K. Kalyan ; Kurien, Jacob ; Mathew, Stanley ; Krishna, C. Murali. / Discrimination of Normal, Benign, and Malignant Breast Tissues by Raman Spectroscopy. In: Biopolymers. 2006 ; Vol. 83, No. 5. pp. 556-569.
@article{148daea41d314bfa93dda792c9ec79b6,
title = "Discrimination of Normal, Benign, and Malignant Breast Tissues by Raman Spectroscopy",
abstract = "Breast cancers are the leading cancers among females. Diagnosis by fine needle aspiration cytology (FNAC) is the gold standard. The widely practiced screening method, mammography, suffers from high false positive results and repeated exposure to harmful ionizing radiation. As with all other cancers survival rates are shown to heavily depend on stage of the cancers (Stage 0, 95{\%}; Stage IV, 75{\%}). Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management. Raman spectra of normal, benign, and malignant breast tissue show significant differences. Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues. Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm-1) is indicated in normal tissue and proteins (stronger amide I, red shifted ΔCH2, broad and strong amide III, 1002, 1033, 1530, 1556 cm-1) are found in benign and malignant tissues. The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm-1) and presence of excess proteins (amide I, amide III, red shifted ΔCH2, 1033, 1002 cm-1) is indicated in benign spectra. The multivariate statistical tool, principal components analysis (PCA) is employed for developing discrimination methods. A score of factor 1 provided a reasonable classification of all three tissue types. The analysis is further fine-tuned by employing Mahalanobis distance and spectral residuals as discriminating parameters. This approach is tested both retrospectively and prospectively. The limit test, which provides the most unambiguous discrimination, is also considered and this approach clearly discriminated all three tissue types. These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues.",
author = "Chowdary, {M. V.P.} and Kumar, {K. Kalyan} and Jacob Kurien and Stanley Mathew and Krishna, {C. Murali}",
year = "2006",
month = "12",
day = "5",
doi = "10.1002/bip.20586",
language = "English",
volume = "83",
pages = "556--569",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Discrimination of Normal, Benign, and Malignant Breast Tissues by Raman Spectroscopy. / Chowdary, M. V.P.; Kumar, K. Kalyan; Kurien, Jacob; Mathew, Stanley; Krishna, C. Murali.

In: Biopolymers, Vol. 83, No. 5, 05.12.2006, p. 556-569.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discrimination of Normal, Benign, and Malignant Breast Tissues by Raman Spectroscopy

AU - Chowdary, M. V.P.

AU - Kumar, K. Kalyan

AU - Kurien, Jacob

AU - Mathew, Stanley

AU - Krishna, C. Murali

PY - 2006/12/5

Y1 - 2006/12/5

N2 - Breast cancers are the leading cancers among females. Diagnosis by fine needle aspiration cytology (FNAC) is the gold standard. The widely practiced screening method, mammography, suffers from high false positive results and repeated exposure to harmful ionizing radiation. As with all other cancers survival rates are shown to heavily depend on stage of the cancers (Stage 0, 95%; Stage IV, 75%). Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management. Raman spectra of normal, benign, and malignant breast tissue show significant differences. Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues. Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm-1) is indicated in normal tissue and proteins (stronger amide I, red shifted ΔCH2, broad and strong amide III, 1002, 1033, 1530, 1556 cm-1) are found in benign and malignant tissues. The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm-1) and presence of excess proteins (amide I, amide III, red shifted ΔCH2, 1033, 1002 cm-1) is indicated in benign spectra. The multivariate statistical tool, principal components analysis (PCA) is employed for developing discrimination methods. A score of factor 1 provided a reasonable classification of all three tissue types. The analysis is further fine-tuned by employing Mahalanobis distance and spectral residuals as discriminating parameters. This approach is tested both retrospectively and prospectively. The limit test, which provides the most unambiguous discrimination, is also considered and this approach clearly discriminated all three tissue types. These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues.

AB - Breast cancers are the leading cancers among females. Diagnosis by fine needle aspiration cytology (FNAC) is the gold standard. The widely practiced screening method, mammography, suffers from high false positive results and repeated exposure to harmful ionizing radiation. As with all other cancers survival rates are shown to heavily depend on stage of the cancers (Stage 0, 95%; Stage IV, 75%). Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management. Raman spectra of normal, benign, and malignant breast tissue show significant differences. Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues. Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm-1) is indicated in normal tissue and proteins (stronger amide I, red shifted ΔCH2, broad and strong amide III, 1002, 1033, 1530, 1556 cm-1) are found in benign and malignant tissues. The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm-1) and presence of excess proteins (amide I, amide III, red shifted ΔCH2, 1033, 1002 cm-1) is indicated in benign spectra. The multivariate statistical tool, principal components analysis (PCA) is employed for developing discrimination methods. A score of factor 1 provided a reasonable classification of all three tissue types. The analysis is further fine-tuned by employing Mahalanobis distance and spectral residuals as discriminating parameters. This approach is tested both retrospectively and prospectively. The limit test, which provides the most unambiguous discrimination, is also considered and this approach clearly discriminated all three tissue types. These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues.

UR - http://www.scopus.com/inward/record.url?scp=33845213072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845213072&partnerID=8YFLogxK

U2 - 10.1002/bip.20586

DO - 10.1002/bip.20586

M3 - Article

C2 - 16897764

AN - SCOPUS:33845213072

VL - 83

SP - 556

EP - 569

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 5

ER -